Randi J Hagerman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/14325/publications.pdf

Version: 2024-02-01

304 papers	22,875 citations	5261 83 h-index	11047 137 g-index
320 all docs	320 docs citations	320 times ranked	9463 citing authors

#	Article	IF	Citations
1	Elevated Levels of FMR1 mRNA in Carrier Males: A New Mechanism of Involvement in the Fragile-X Syndrome. American Journal of Human Genetics, 2000, 66, 6-15.	2.6	756
2	Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, Clinical, and Neuroimaging Correlates. American Journal of Human Genetics, 2003, 72, 869-878.	2.6	720
3	Penetrance of the Fragile Xâ€"Associated Tremor/Ataxia Syndrome in a Premutation Carrier Population. JAMA - Journal of the American Medical Association, 2004, 291, 460.	3.8	571
4	Advances in the Treatment of Fragile X Syndrome. Pediatrics, 2009, 123, 378-390.	1.0	513
5	Fragile X syndrome. Nature Reviews Disease Primers, 2017, 3, 17065.	18.1	490
6	The Fragile-X Premutation: A Maturing Perspective. American Journal of Human Genetics, 2004, 74, 805-816.	2.6	485
7	Autism Profiles of Males With Fragile X Syndrome. American Journal on Intellectual and Developmental Disabilites, 2008, 113, 427-438.	2.7	357
8	Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056. Science Translational Medicine, 2011, 3, 64ra1.	5.8	344
9	FMRP expression as a potential prognostic indicator in fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 84, 250-261.	2.4	318
10	The Gut Microbiota and Autism Spectrum Disorders. Frontiers in Cellular Neuroscience, 2017, 11, 120.	1.8	311
11	Fragile Xâ€associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Movement Disorders, 2007, 22, 2018-2030.	2.2	306
12	Autism Spectrum Disorders and Attention-Deficit/Hyperactivity Disorder in Boys with the Fragile X Premutation. Journal of Developmental and Behavioral Pediatrics, 2006, 27, S137-S144.	0.6	292
13	Expanded clinical phenotype of women with the FMR1 premutation. American Journal of Medical Genetics, Part A, 2008, 146A, 1009-1016.	0.7	290
14	Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial. Science Translational Medicine, 2012, 4, 152ra127.	5.8	289
15	Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurology, The, 2013, 12, 786-798.	4.9	288
16	Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. American Journal of Neuroradiology, 2002, 23, 1757-66.	1.2	272
17	Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. Journal of Neurodevelopmental Disorders, 2011, 3, 57-67.	1.5	269
18	Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. Journal of Clinical Investigation, 2012, 122, 4314-4322.	3.9	269

#	Article	IF	Citations
19	FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Medicine, 2012, 4, 100.	3.6	258
20	Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature Reviews Drug Discovery, 2018, 17, 280-299.	21.5	247
21	The fragile X premutation: into the phenotypic fold. Current Opinion in Genetics and Development, 2002, 12, 278-283.	1.5	228
22	An analysis of autism in fifty males with the fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 359-374.	2.4	224
23	Fragile X-associated tremor/ataxia syndrome â€" features, mechanisms and management. Nature Reviews Neurology, 2016, 12, 403-412.	4.9	221
24	High functioning fragile X males: Demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. American Journal of Medical Genetics Part A, 1994, 51, 298-308.	2.4	213
25	Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurology, The, 2007, 6, 45-55.	4.9	212
26	A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2013, 34, 147-155.	0.6	212
27	Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Science Translational Medicine, 2016, 8, 321ra5.	5.8	210
28	Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Molecular Autism, 2010, 1, 12.	2.6	204
29	Transcription of the FMR1 gene in individuals with fragile X syndrome. American Journal of Medical Genetics Part A, 2000, 97, 195-203.	2.4	192
30	Molecular-clinical correlations in males with an expanded FMR1 mutation. American Journal of Medical Genetics Part A, 1996, 64, 388-394.	2.4	182
31	Lessons from Fragile X Regarding Neurobiology, Autism, and Neurodegeneration. Journal of Developmental and Behavioral Pediatrics, 2006, 27, 63-74.	0.6	181
32	Heterozygous fragile X female: Historical, physical, cognitive, and cytogenetic features. American Journal of Medical Genetics Part A, 1991, 38, 269-274.	2.4	178
33	Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.. Neuropsychology, 2008, 22, 48-60.	1.0	167
34	Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochemical Journal, 2010, 429, 545-552.	1.7	162
35	Lifetime Prevalence of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Journal of Clinical Psychiatry, 2011, 72, 175-182.	1.1	162
36	Widespread RNA editing dysregulation in brains from autistic individuals. Nature Neuroscience, 2019, 22, 25-36.	7.1	161

#	Article	IF	Citations
37	Psychiatric Phenotype of the Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) in Males. Journal of Clinical Psychiatry, 2006, 67, 87-94.	1.1	158
38	A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. Journal of Neurodevelopmental Disorders, 2009, 1, 33-45.	1.5	156
39	Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels ofFMR1 messenger RNA. American Journal of Medical Genetics Part A, 2000, 94, 232-236.	2.4	154
40	AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genetics in Medicine, 2012, 14, 729-736.	1.1	152
41	Fragile X spectrum disorders. Intractable and Rare Diseases Research, 2014, 3, 134-146.	0.3	150
42	The Efficacy of Melatonin for Sleep Problems in Children with Autism, Fragile X Syndrome, or Autism and Fragile X Syndrome. Journal of Clinical Sleep Medicine, 2009, 05, 145-150.	1.4	149
43	A controlled trial of stimulant medication in children with the fragile X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 377-392.	2.4	146
44	Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Human Molecular Genetics, 2010, 19, 196-208.	1.4	143
45	Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. Rna, 2002, 8, 1482-8.	1.6	143
46	Fragile X checklist. American Journal of Medical Genetics Part A, 1991, 38, 283-287.	2.4	142
47	High MMPâ€9 activity levels in fragile X syndrome are lowered by minocycline. American Journal of Medical Genetics, Part A, 2013, 161, 1897-1903.	0.7	140
48	The Prader-Willi Phenotype of Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2007, 28, 133-138.	0.6	139
49	Fragile Xâ€“associated tremor/ataxia syndrome. Annals of the New York Academy of Sciences, 2015, 1338, 58-70.	1.8	139
50	CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 566-569.	1.1	138
51	Effect of CX516, an AMPA-Modulating Compound, on Cognition and Behavior in Fragile X Syndrome: AControlled Trial. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 525-540.	0.7	136
52	Fragile X Syndrome. Current Genomics, 2011, 12, 216-224.	0.7	136
53	Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal of Neurodevelopmental Disorders, 2017, 9, 3.	1.5	135
54	Progression of tremor and ataxia in male carriers of theFMR1 premutation. Movement Disorders, 2007, 22, 203-206.	2.2	134

#	Article	IF	Citations
55	Fragile X-Associated Neuropsychiatric Disorders (FXAND). Frontiers in Psychiatry, 2018, 9, 564.	1.3	132
56	Signaling defects in iPSC-derived fragile X premutation neurons. Human Molecular Genetics, 2012, 21, 3795-3805.	1.4	129
57	Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). Journal of the Neurological Sciences, 2006, 248, 227-233.	0.3	126
58	Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clinical Interventions in Aging, 2008, Volume 3, 251-262.	1.3	122
59	Cognitive profiles of boys with the fragile X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 191-200.	2.4	121
60	Associated features in females with an FMR1 premutation. Journal of Neurodevelopmental Disorders, 2014, 6, 30.	1.5	116
61	Cognitive profiles and the spectrum of clinical manifestations in heterozygous fra(X) females. American Journal of Medical Genetics Part A, 1986, 23, 139-156.	2.4	115
62	Effect of the Fragile X Status Categories and the Fragile X Mental Retardation Protein Levels on Executive Functioning in Males and Females With Fragile X.. Neuropsychology, 2003, 17, 646-657.	1.0	113
63	Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics, 2012, 131, 581-589.	1.8	108
64	Tremor and ataxia in fragile X premutation carriers: Blinded videotape study. Annals of Neurology, 2003, 53, 616-623.	2.8	104
65	Recent advances in fragile X: a model for autism and neurodegeneration. Current Opinion in Psychiatry, 2005, 18, 490-496.	3.1	103
66	Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathologica, 2011, 122, 467-479.	3.9	102
67	Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Neuropsychopharmacology, 2018, 43, 503-512.	2.8	102
68	Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal of Neurodevelopmental Disorders, 2017, 9, 7.	1.5	99
69	Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Human Molecular Genetics, 2011, 20, 3079-3092.	1.4	98
70	The challenges of clinical trials in fragile X syndrome. Psychopharmacology, 2014, 231, 1237-1250.	1.5	98
71	Molecular/clinical correlations in females with fragile X. , 1996, 64, 340-345.		94
72	Testicular and Pituitary Inclusion Formation in Fragile X Associated Tremor/Ataxia Syndrome. Journal of Urology, 2007, 177, 1434-1437.	0.2	94

#	Article	IF	Citations
73	Dementia in fragile Xâ€associated tremor/ataxia syndrome (FXTAS): Comparison with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1138-1144.	1.1	92
74	Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Human Molecular Genetics, 2012, 21, 2923-2935.	1.4	92
75	Electrocortical changes associated with minocycline treatment in fragile X syndrome. Journal of Psychopharmacology, 2013, 27, 956-963.	2.0	92
76	Fragile X Syndrome and Targeted Treatment Trials. Results and Problems in Cell Differentiation, 2012, 54, 297-335.	0.2	91
77	Side Effects of Minocycline Treatment in Patients With Fragile X Syndrome and Exploration of Outcome Measures. American Journal on Intellectual and Developmental Disabilities, 2010, 115, 433-443.	0.8	90
78	Behavioral and Psychiatric Disorders in Adult Male Carriers of Fragile X. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, 33, 256-264.	0.3	89
79	Neuropathic features in fragile X premutation carriers. American Journal of Medical Genetics, Part A, 2007, 143A, 19-26.	0.7	89
80	Speech disturbances (cluttering) in mildly impaired males with the Martin-Bell/fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 195-206.	2.4	88
81	A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome. Brain, 2011, 134, 863-878.	3.7	87
82	Longitudinal IQ changes in fragile X males. American Journal of Medical Genetics Part A, 1989, 33, 513-518.	2.4	86
83	Immuneâ€mediated disorders among women carriers of fragile X premutation alleles. American Journal of Medical Genetics, Part A, 2012, 158A, 2473-2481.	0.7	86
84	Clinical and molecular implications of mosaicism in FMR1 full mutations. Frontiers in Genetics, 2014, 5, 318.	1.1	86
85	Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Movement Disorders, 2007, 22, 645-650.	2.2	84
86	Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. General Hospital Psychiatry, 2007, 29, 349-356.	1.2	83
87	The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 853-869.	0.8	83
88	The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. Journal of Clinical Sleep Medicine, 2009, 5, 145-50.	1.4	82
89	An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Journal of Psychiatric Research, 2011, 45, 36-43.	1.5	80
90	Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neurobiology of Disease, 2020, 136, 104740.	2.1	80

#	Article	IF	Citations
91	Tissue heterogeneity of theFMR1 mutation in a high-functioning male with fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 84, 233-239.	2.4	79
92	Emotional and neurocognitive deficits in fragile X. American Journal of Medical Genetics Part A, 1994, 51, 378-385.	2.4	76
93	Adult fragile X syndrome: Neuropsychology, brain anatomy, and metabolism. American Journal of Medical Genetics Part A, 1995, 60, 480-493.	2.4	76
94	CGG allele size somatic mosaicism and methylation inFMR1premutation alleles. Journal of Medical Genetics, 2014, 51, 309-318.	1.5	76
95	Emerging topics in FXTAS. Journal of Neurodevelopmental Disorders, 2014, 6, 31.	1.5	76
96	Developmental Implications of Changing Trajectories of IQ in Males with Fragile X Syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 1990, 29, 214-219.	0.3	75
97	Abnormal Nerve Conduction Features in Fragile X Premutation Carriers. Archives of Neurology, 2008, 65, 495.	4.9	75
98	FMR1 premutation and full mutation molecular mechanisms related to autism. Journal of Neurodevelopmental Disorders, 2011, 3, 211-224.	1.5	74
99	Symptoms of Autism in Males with Fragile X Syndrome: A Comparison to Nonsyndromic ASD Using Current ADI-R Scores. Journal of Autism and Developmental Disorders, 2015, 45, 1925-1937.	1.7	74
100	Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene. Movement Disorders, 2011, 26, 1329-1336.	2.2	72
101	Fragile X syndrome: A review of clinical management. Intractable and Rare Diseases Research, 2016, 5, 145-157.	0.3	70
102	Neuropathologic features in the hippocampus and cerebellum of three older men with fragile X syndrome. Molecular Autism, 2011, 2, 2.	2.6	68
103	A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. Journal of Neurodevelopmental Disorders, 2017, 9, 26.	1.5	67
104	Psychiatric symptoms in boys with fragile X syndrome: A comparison with nonsyndromic autism spectrum disorder. Research in Developmental Disabilities, 2014, 35, 1072-1086.	1.2	65
105	A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal of Developmental and Behavioral Pediatrics, 2016, 37, 619-628.	0.6	65
106	Rare FMR1 gene mutations causing fragile X syndrome: A review. American Journal of Medical Genetics, Part A, 2018, 176, 11-18.	0.7	65
107	Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile Xâ€associated Tremor/Ataxia syndrome: A controlled study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 859-872.	1.1	64
108	Fragile Xâ€“Associated Tremor/Ataxia Syndrome. JAMA Neurology, 2013, 70, 1022.	4.5	64

#	Article	IF	Citations
109	Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 241-262.	2.4	62
110	Modulation of the GABAergic pathway for the treatment of fragile X syndrome. Neuropsychiatric Disease and Treatment, 2014, 10, 1769.	1.0	62
111	Aortic root dilatation and mitral valve prolapse in the fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 189-194.	2.4	60
112	Neuropsychological dysfunction among affected heterozygous fragile X females. American Journal of Medical Genetics Part A, 1990, 35, 28-35.	2.4	60
113	Consideration of connective tissue dysfunction in the fragile X syndrome. American Journal of Medical Genetics Part A, 1984, 17, 111-121.	2.4	59
114	Neuropathy as a presenting feature in fragile Xâ€associated tremor/ataxia syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 2256-2260.	0.7	59
115	Aging in fragile X syndrome. Journal of Neurodevelopmental Disorders, 2010, 2, 70-76.	1.5	59
116	Altered Redox Mitochondrial Biology in the Neurodegenerative Disorder Fragile X-Tremor/Ataxia Syndrome: Use of Antioxidants in Precision Medicine. Molecular Medicine, 2016, 22, 548-559.	1.9	56
117	Autism in fragile X females. American Journal of Medical Genetics Part A, 1986, 23, 375-380.	2.4	55
118	A Quantitative ELISA Assay for the Fragile X Mental Retardation 1 Protein. Journal of Molecular Diagnostics, 2009, 11, 281-289.	1.2	52
119	Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE, 2019, 14, e0226811.	1.1	52
120	Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Pathophysiology and Clinical Implications. International Journal of Molecular Sciences, 2020, 21, 4391.	1.8	52
121	Strong similarities of theFMR1 mutation in multiple tissues: Postmortem studies of a male with a full mutation and a male carrier of a premutation. American Journal of Medical Genetics Part A, 1999, 84, 240-244.	2.4	51
122	Sleep apnea in fragile X premutation carriers with and without FXTAS. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 923-928.	1.1	51
123	Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology, 2011, 50, 2233-2236.	0.9	51
124	Age-Dependent Structural Connectivity Effects in Fragile X Premutation. Archives of Neurology, 2012, 69, 482-9.	4.9	51
125	Protein synthesis levels are increased in a subset of individuals with fragile X syndrome. Human Molecular Genetics, 2018, 27, 2039-2051.	1.4	51
126	A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. , 1996, 64, 350-355.		50

#	Article	IF	Citations
127	A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatric Neurology, 2020, 110, 30-41.	1.0	50
128	Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome. Science Signaling, 2016, 9, ra58.	1.6	49
129	Composition of the Intranuclear Inclusions of Fragile X-associated Tremor/Ataxia Syndrome. Acta Neuropathologica Communications, 2019, 7, 143.	2.4	48
130	Fragile X syndrome. Colombia Medica, 2014, 45, 190-8.	0.7	48
131	Trajectories and profiles of adaptive behavior in males with fragile X syndrome: Multicenter studies. Journal of Autism and Developmental Disorders, 1996, 26, 287-301.	1.7	47
132	Size and methylation mosaicism in males with Fragile X syndrome. Expert Review of Molecular Diagnostics, 2017, 17, 1023-1032.	1.5	47
133	An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics, 2022, 19, 248-262.	2.1	47
134	Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation. Neurobiology of Aging, 2017, 55, 11-19.	1.5	46
135	Translating Molecular Advances in Fragile X Syndrome Into Therapy. Journal of Clinical Psychiatry, 2014, 75, e294-e307.	1.1	46
136	Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 12.	1.5	44
137	Memantine for Fragile Xâ€“Associated Tremor/Ataxia Syndrome. Journal of Clinical Psychiatry, 2014, 75, 264-271.	1.1	44
138	Early Detection of Fragile X Syndrome: Applications of a Novel Approach for Improved Quantitative Methylation Analysis in Venous Blood and Newborn Blood Spots. Clinical Chemistry, 2014, 60, 963-973.	1.5	43
139	Evaluation of the neuroactive steroid ganaxolone on social and repetitive behaviors in the BTBR mouse model of autism. Psychopharmacology, 2016, 233, 309-323.	1.5	43
140	Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): Revisited. Parkinsonism and Related Disorders, 2014, 20, 456-459.	1.1	42
141	Hypertension in FMR1 premutation males with and without fragile Xâ€associated tremor/ataxia syndrome (FXTAS). American Journal of Medical Genetics, Part A, 2012, 158A, 1304-1309.	0.7	41
142	Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome. Brain Research, 2015, 1598, 88-96.	1.1	41
143	Altered Bioenergetics in Primary Dermal Fibroblasts from Adult Carriers of the FMR1 Premutation Before the Onset of the Neurodegenerative Disease Fragile X-Associated Tremor/Ataxia Syndrome. Cerebellum, 2016, 15, 552-564.	1.4	41
144	Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. NeuroToxicology, 2010, 31, 399-402.	1.4	40

#	Article	IF	Citations
145	Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disorders & Therapy, 2014, 03, .	0.1	40
146	Treatment of the psychiatric problems associated with fragile X syndrome. Current Opinion in Psychiatry, 2015, 28, 107-112.	3.1	40
147	Discourse Processing in Women with Fragile X Syndrome: Evidence for a Deficit Establishing Coherence. Cognitive Neuropsychology, 2001, 18, 1-18.	0.4	39
148	Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome. Case Reports in Genetics, 2012, 2012, 1-4.	0.1	39
149	Metformin treatment in young children with fragile X syndrome. Molecular Genetics & Genomic Medicine, 2019, 7, e956.	0.6	39
150	Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. Intractable and Rare Diseases Research, 2015, 4, 123-130.	0.3	39
151	Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation. Biochemical Journal, 2016, 473, 3871-3888.	1.7	38
152	Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families. Pediatrics, 2017, 139, S172-S182.	1.0	38
153	Fragile X syndrome and fragile X-associated disorders. F1000Research, 2017, 6, 2112.	0.8	38
154	Sertraline May Improve Language Developmental Trajectory in Young Children with Fragile X Syndrome: A Retrospective Chart Review. Autism Research & Treatment, 2012, 2012, 1-8.	0.1	37
155	Intranuclear inclusions in a fragile X mosaic male. Translational Neurodegeneration, 2013, 2, 10.	3.6	37
156	Best Practices in Fragile X Syndrome Treatment Development. Brain Sciences, 2018, 8, 224.	1.1	37
157	Memantine Effects on Verbal Memory in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS): a Double-Blind Brain Potential Study. Neuropsychopharmacology, 2014, 39, 2760-2768.	2.8	36
158	Cognitive profiles of the carrier fragile X woman. American Journal of Medical Genetics Part A, 1991, 38, 505-508.	2.4	35
159	Update on the Clinical, Radiographic, and Neurobehavioral Manifestations in FXTAS and FMR1 Premutation Carriers. Cerebellum, 2016, 15, 578-586.	1.4	35
160	Mental impairment in cytogenetically positive fragile X females. American Journal of Medical Genetics Part A, 1991, 38, 503-504.	2.4	34
161	Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases. Intractable and Rare Diseases Research, 2014, 3, 162-165.	0.3	34
162	Testing for Fragile X Gene Mutations Throughout the Life Span. JAMA - Journal of the American Medical Association, 2008, 300, 2419.	3.8	33

#	Article	IF	Citations
163	Rare Intranuclear Inclusions in the Brains of 3 Older Adult Males With Fragile X Syndrome: Implications for the Spectrum of Fragile X-Associated Disorders. Journal of Neuropathology and Experimental Neurology, 2011, 70, 462-469.	0.9	33
164	Warburg effect linked to cognitiveâ€executive deficits inFMR1premutation. FASEB Journal, 2016, 30, 3334-3351.	0.2	33
165	Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Scientific Reports, 2018, 8, 16970.	1.6	33
166	Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature. Cannabis and Cannabinoid Research, 2019, 4, 3-9.	1.5	32
167	A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Movement Disorders, 2013, 28, 1278-1284.	2.2	31
168	Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles. NeuroImage, 2013, 65, 288-298.	2.1	31
169	Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome. Neurobiology of Aging, 2014, 35, 1189-1197.	1.5	31
170	Distance delivery of a spoken language intervention for school-aged and adolescent boys with fragile X syndrome. Developmental Neurorehabilitation, 2018, 21, 48-63.	0.5	31
171	New Targeted Treatments for Fragile X Syndrome. Current Pediatric Reviews, 2019, 15, 251-258.	0.4	31
172	Tremor/Ataxia syndrome in fragile X carrier males. Movement Disorders, 2002, 17, 744-745.	2.2	30
173	Clinical conundrums in fragile X syndrome. Nature Genetics, 1992, 1, 157-158.	9.4	29
174	Towards an understanding of neuropsychiatric manifestations in fragile X premutation carriers. Future Neurology, 2014, 9, 227-239.	0.9	29
175	Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome. Brain and Development, 2017, 39, 483-492.	0.6	29
176	Experiences and attitudes concerning genetic testing and insurance in a Colorado population: A survey of families diagnosed with fragile X syndrome. , 1996, 64, 378-381.		28
177	Neural Substrates of Executive Dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): a Brain Potential Study. Cerebral Cortex, 2013, 23, 2657-2666.	1.6	28
178	High functioning male with fragile X syndrome and fragile Xâ€associated tremor/ataxia syndrome. American Journal of Medical Genetics, Part A, 2015, 167, 2154-2161.	0.7	28
179	Review of targeted treatments in fragile X syndrome. Intractable and Rare Diseases Research, 2016, 5, 158-167.	0.3	28
180	Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. Molecular Neurobiology, 2019, 56, 3702-3713.	1.9	28

#	Article	IF	Citations
181	Aortic hypoplasia and cardiac valvular abnormalities in a boy with fragile X syndrome. American Journal of Medical Genetics Part A, 1988, 30, 83-98.	2.4	27
182	Psychopharmacological interventions in fragile X syndrome, fetal alcohol syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velocardiofacial syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 1999, 5, 305-313.	3.5	27
183	Genetic cluster of fragile X syndrome in a Colombian district. Journal of Human Genetics, 2018, 63, 509-516.	1.1	27
184	Fragile X Syndrome: From Molecular Aspect to Clinical Treatment. International Journal of Molecular Sciences, 2022, 23, 1935.	1.8	27
185	Improving Fragile X-Associated Tremor/Ataxia Syndrome Symptoms With Memantine and Venlafaxine. Journal of Clinical Psychopharmacology, 2010, 30, 642-644.	0.7	26
186	Immune Dysregulation as a Cause of Autoinflammation in Fragile X Premutation Carriers: Link between FMRI CGG Repeat Number and Decreased Cytokine Responses. PLoS ONE, 2014, 9, e94475.	1.1	26
187	Fragile Xâ€“Associated Tremor/Ataxia Syndrome in a Man in His 30s. JAMA Neurology, 2015, 72, 1070.	4.5	26
188	Memantine Improves Attentional Processes in Fragile X-Associated Tremor/Ataxia Syndrome: Electrophysiological Evidence from a Randomized Controlled Trial. Scientific Reports, 2016, 6, 21719.	1.6	26
189	Phenotypes of hypofrontality in older female fragile x premutation carriers. Annals of Neurology, 2013, 74, n/a-n/a.	2.8	25
190	Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable and Rare Diseases Research, 2014, 3, 110-117.	0.3	25
191	Fragile X syndrome and connective tissue dysregulation. Clinical Genetics, 2019, 95, 262-267.	1.0	25
192	Abnormal N400 word repetition effects in fragile X-associated tremor/ataxia syndrome. Brain, 2010, 133, 1438-1450.	3.7	24
193	Genomic studies in fragile X premutation carriers. Journal of Neurodevelopmental Disorders, 2014, 6, 27.	1.5	24
194	The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery. Stem Cells Translational Medicine, 2014, 3, 1275-1286.	1.6	24
195	Methadone use in a male with the FMRI premutation and FXTAS. American Journal of Medical Genetics, Part A, 2015, 167, 1354-1359.	0.7	24
196	Premutation in the Fragile X Mental Retardation 1 (FMR1) Gene Affects Maternal Zn-milk and Perinatal Brain Bioenergetics and Scaffolding. Frontiers in Neuroscience, 2016, 10, 159.	1.4	24
197	Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers. Frontiers in Molecular Neuroscience, 2016, 9, 71.	1.4	24
198	Invited editorial comment: Cognitive variability in the fragile X syndrome. American Journal of Medical Genetics Part A, 1987, 28, 13-15.	2.4	23

#	Article	IF	Citations
199	A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. Frontiers in Psychiatry, 2019, 10, 810.	1.3	22
200	Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome. PLoS ONE, 2019, 14, e0209984.	1.1	22
201	Fragile X-associated tremor/ataxia syndrome: pathophysiology and management. Current Opinion in Neurology, 2021, 34, 541-546.	1.8	22
202	Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers. Current Psychiatry Reviews, 2013, 9, 65-71.	0.9	21
203	ERP abnormalities elicited by word repetition in fragile X-associated tremor/ataxia syndrome (FXTAS) and amnestic MCI. Neuropsychologia, 2014, 63, 34-42.	0.7	21
204	Developmental profiles of infants with an FMR1 premutation. Journal of Neurodevelopmental Disorders, 2016, 8, 40.	1.5	21
205	Psychiatric disorders among women with theâ€‰fragile X premutation without children affected by fragile X syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 1139-1147.	1.1	21
206	Cognitive and behavioral improvement in adults with fragile X syndrome treated with metforminâ€two cases. Molecular Genetics & Genomic Medicine, 2019, 7, e00745.	0.6	21
207	Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. Brain Sciences, 2020, 10, 629.	1.1	21
208	Fragile X Premutation. Journal of Neurodevelopmental Disorders, 2014, 6, 22.	1.5	20
209	Phenobarbital use and neurological problems in FMR1 premutation carriers. NeuroToxicology, 2016, 53, 141-147.	1.4	20
210	De novo and biallelic DEAF1 variants cause a phenotypic spectrum. Genetics in Medicine, 2019, 21, 2059-2069.	1.1	20
211	Elevated FMR1-mRNA and lowered FMRP â€“ A double-hit mechanism for psychiatric features in men with FMR1 premutations. Translational Psychiatry, 2020, 10, 205.	2.4	20
212	Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder. Current Pharmaceutical Design, 2015, 21, 4972-4979.	0.9	20
213	Oral findings in fragile X syndrome. American Journal of Medical Genetics Part A, 1986, 23, 179-187.	2.4	19
214	Microglial cell activation and senescence are characteristic of the pathology FXTAS. Movement Disorders, 2018, 33, 1887-1894.	2.2	19
215	Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews, 2013, 9, 59-64.	0.9	18
216	Robust Machine Learning-Based Correction on Automatic Segmentation of the Cerebellum and Brainstem. PLoS ONE, 2016, 11, e0156123.	1.1	18

#	Article	IF	Citations
217	Sensoryâ€modulation disruption, electrodermal responses, and functional behaviors. Developmental Medicine and Child Neurology, 1999, 41, 608-615.	1.1	17
218	Impact of FMR1 Premutation on Neurobehavior and Bioenergetics in Young Monozygotic Twins. Frontiers in Genetics, 2018, 9, 338.	1.1	17
219	Cerebral Microbleeds in Fragile Xâ€“Associated Tremor/Ataxia Syndrome. Movement Disorders, 2021, 36, 1935-1943.	2.2	17
220	Fragile X Syndrome: Psychiatric Manifestations, Assessment and Emerging Therapies. Current Psychiatry Reviews, 2013, 9, 53-58.	0.9	16
221	The neurobiology of the Prader-Willi phenotype of fragile X syndrome. Intractable and Rare Diseases Research, 2016, 5, 255-261.	0.3	16
222	Middle Cerebellar Peduncle Widthâ€”A Novel MRI Biomarker for FXTAS?. Frontiers in Neuroscience, 2018, 12, 379.	1.4	16
223	General Anesthetic Use in Fragile X Spectrum Disorders. Journal of Neurosurgical Anesthesiology, 2019, 31, 285-290.	0.6	16
224	SÃndrome X frÃ¡gil: presentaciÃ³n clÃnica, patologÃa y tratamiento. Gaceta Medica De Mexico, 2019, 156, 60-66.	0.5	16
225	Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 328-337.	1.2	15
226	Fragile X checklists: A metaâ€analysis and development of a simplified universal clinical checklist. Molecular Genetics & Genomic Medicine, 2018, 6, 526-532.	0.6	15
227	Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments. Neurotherapeutics, 2021, 18, 265-283.	2.1	15
228	Maternal Consequences of the Detection of Fragile X Carriers in Newborn Screening. Pediatrics, 2015, 136, e433-e440.	1.0	14
229	Aging in Fragile X Premutation Carriers. Cerebellum, 2016, 15, 587-594.	1.4	14
230	Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning. Clinical Neuropsychologist, 2016, 30, 944-959.	1.5	14
231	Epilepsy drives autism in neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2013, 55, 101-102.	1.1	13
232	A feasibility trial of Cogmed working memory training in fragile X syndrome. Journal of Pediatric Genetics, 2015, 03, 147-156.	0.3	13
233	Clinical and molecular correlates in fragile X premutation females. ENeurologicalSci, 2017, 7, 49-56.	0.5	13
234	Presence of Middle Cerebellar Peduncle Sign in FMR1 Premutation Carriers Without Tremor and Ataxia. Frontiers in Neurology, 2018, 9, 695.	1.1	13

#	Article	IF	Citations
235	Women with Fragile Xâ€“associated Tremor/Ataxia Syndrome. Movement Disorders Clinical Practice, 2020, 7, 910-919.	0.8	13
236	Parkinsonism Versus Concomitant Parkinson's Disease in Fragile Xâ€“Associated Tremor/Ataxia Syndrome. Movement Disorders Clinical Practice, 2020, 7, 413-418.	0.8	13
237	Fragile X syndrome. Current Biology, 2021, 31, R273-R275.	1.8	13
238	Detection of skewed X-chromosome inactivation in Fragile X syndrome and X chromosome aneuploidy using quantitative melt analysis. Expert Reviews in Molecular Medicine, 2015, 17, e13.	1.6	12
239	Psychosis and catatonia in fragile X: Case report and literature review. Intractable and Rare Diseases Research, 2015, 4, 139-146.	0.3	12
240	Characterization of the Metabolic, Clinical and Neuropsychological Phenotype of Female Carriers of the Premutation in the X-Linked FMR1 Gene. Frontiers in Molecular Biosciences, 2020, 7, 578640.	1.6	12
241	Effects of labeling and pointing on object gaze in boys with fragile X syndrome: An eye-tracking study. Research in Developmental Disabilities, 2014, 35, 2658-2672.	1.2	11
242	Cardiovascular Problems in the Fragile X Premutation. Frontiers in Genetics, 2020, 11, 586910.	1.1	11
243	Human Cerebral Cortex Proteome of Fragile X-Associated Tremor/Ataxia Syndrome. Frontiers in Molecular Biosciences, 2020, 7, 600840.	1.6	11
244	Compound heterozygous female with fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 83, 318-321.	2.4	10
245	Use of Emotional Cues for Lexical Learning: A Comparison of Autism Spectrum Disorder and Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2015, 45, 1042-1061.	1.7	10
246	Children With Fragile X Syndrome Display Threat-Specific Biases Toward Emotion. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 487-492.	1.1	10
247	Fragile X Syndrome: Prevalence, Treatment, and Prevention in China. Frontiers in Neurology, 2017, 8, 254.	1.1	10
248	Increased severity of fragile X spectrum disorders in the agricultural community of Ricaurte, Colombia. International Journal of Developmental Neuroscience, 2019, 72, 1-5.	0.7	10
249	Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with FMR1 normal and premutation alleles. Neurobiology of Aging, 2020, 86, 27-38.	1.5	10
250	Cerebellar-cortical function and connectivity during sensorimotor behavior in aging FMR1 gene premutation carriers. NeuroImage: Clinical, 2020, 27, 102332.	1.4	10
251	Deficits in Prenatal Serine Biosynthesis Underlie the Mitochondrial Dysfunction Associated with the Autism-Linked FMR1 Gene. International Journal of Molecular Sciences, 2021, 22, 5886.	1.8	10
252	Effect of Speaker Gaze on Word Learning in Fragile X Syndrome: A Comparison With Nonsyndromic Autism Spectrum Disorder. Journal of Speech, Language, and Hearing Research, 2015, 58, 383-395.	0.7	9

#	Article	IF	Citations
253	Sulforaphane improves mitochondrial metabolism in fibroblasts from patients with fragile X-associated tremor and ataxia syndrome. Neurobiology of Disease, 2021, 157, 105427.	2.1	9
254	FMRP expression as a potential prognostic indicator in fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 84, 250-261.	2.4	9
255	Alcohol use dependence in fragile X syndrome. Intractable and Rare Diseases Research, 2016, 5, 207-213.	0.3	8
256	Genetics, white matter, and cognition. Neurology, 2017, 88, 2070-2071.	1.5	8
257	Prenatal Diagnosis of Fragile X: Can a Full Mutation Allele in the FMR1 Gene Contract to a Normal Size?. Frontiers in Genetics, 2017, 8, 158.	1.1	8
258	Spontaneous Coronary Artery DissectionÂin Females With the FragileÂXÂFMR1ÂPremutation. JACC: Case Reports, 2020, 2, 40-44.	0.3	8
259	Brain Atrophy and White Matter Damage Linked to Peripheral Bioenergetic Deficits in the Neurodegenerative Disease FXTAS. International Journal of Molecular Sciences, 2021, 22, 9171.	1.8	8
260	Case Report: Coexistence of Alzheimer-Type Neuropathology in Fragile X-Associated Tremor Ataxia Syndrome. Frontiers in Neuroscience, 2021, 15, 720253.	1.4	8
261	Psychiatric Disorders Associated with FXTAS. Current Psychiatry Reviews, 2013, 9, 59-64.	0.9	8
262	Neuropsychological changes in FMR1 premutation carriers and onset of fragile X-associated tremor/ataxia syndrome. Journal of Neurodevelopmental Disorders, 2022, 14, 23.	1.5	8
263	Emotion Potentiated Startle in Fragile X Syndrome. Journal of Autism and Developmental Disorders, 2014, 44, 2536-2546.	1.7	7
264	Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimerâ€™s Disease . Clinical Interventions in Aging, 2020, Volume 15, 285-292.	1.3	7
265	Ataxia as the Major Manifestation of Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): Case Series. Biomedicines, 2020, 8, 136.	1.4	7
266	Double Genetic Hit: Fragile X Syndrome and Partial Deletion of Protein Patched Homolog 1 Antisense as Cause of Severe Autism Spectrum Disorder. Journal of Developmental and Behavioral Pediatrics, 2020, 41, 724-728.	0.6	7
267	Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation. Frontiers in Neurology, 2022, 13, 797649.	1.1	7
268	Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications. Journal of Neurology, 0, , .	1.8	7
269	Expanding the role of the genetic counselor. , 1996, 64, 382-387.		6
270	Fatigue and body mass index in the Fragile X premutation carrier. Fatigue: Biomedicine, Health and Behavior, 2014, 2, 64-72.	1.2	6

#	Article	IF	Citations
271	Cliniciansâ€™ experiences with the fragile X clinical and research consortium. American Journal of Medical Genetics, Part A, 2016, 170, 3138-3143.	0.7	6
272	Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. Annual Review of Pharmacology and Toxicology, 2022, 62, 365-381.	4.2	6
273	FMRP Levels in Human Peripheral Blood Leukocytes Correlates with Intellectual Disability. Diagnostics, 2021, 11, 1780.	1.3	6
274	Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome. Frontiers in Psychiatry, 2021, 12, 762915.	1.3	6
275	Participation of underrepresented minority children in clinical trials for Fragile X syndrome and other neurodevelopmental disorders. Intractable and Rare Diseases Research, 2014, 3, 147-152.	0.3	5
276	Axonal neuropathy in female carriers of the fragile X premutation with fragile xâ€“associated tremor ataxia syndrome. Muscle and Nerve, 2015, 52, 234-239.	1.0	5
277	<scp>T</scp>wo <scp>FMR</scp>1 premutation cases without nuclear inclusions. Movement Disorders, 2017, 32, 1328-1329.	2.2	5
278	Fragile X-associated neuropsychiatric disorders: a case report. Future Neurology, 2019, 14, FNL14.	0.9	5
279	Fragile X associated neuropsychiatric disorders in a male without FXTAS. Intractable and Rare Diseases Research, 2020, 9, 113-118.	0.3	5
280	Developmental aspects of FXAND in a man with the FMR1 premutation. Molecular Genetics & Genomic Medicine, 2020, 8, e1050.	0.6	5
281	Hypermobile Ehlers-Danlos syndrome (hEDS) phenotype in fragile X premutation carriers: case series. Journal of Medical Genetics, 2022, 59, 687-690.	1.5	5
282	Tissue heterogeneity of the FMR1 mutation in a highâ€functioning male with fragile X syndrome. American Journal of Medical Genetics Part A, 1999, 84, 233-239.	2.4	5
283	Fragile X Premutation: Medications, Therapy and Lifestyle Advice. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1689-1699.	0.4	5
284	Surveillance and prevalence of fragile X syndrome in Indonesia. Intractable and Rare Diseases Research, 2021, 10, 11-16.	0.3	4
285	Treatment and Management of FXTAS. , 2016, , 181-197.		4
286	Fragile X syndrome and an isodicentric X chromosome in a woman with multiple anomalies, developmental delay, and normal pubertal development. , 1999, 85, 197-201.		3
287	Identification of a male with fragile X syndrome through newborn screening. Intractable and Rare Diseases Research, 2015, 4, 198-202.	0.3	3
288	Cortical gyrification and its relationships with molecular measures and cognition in children with the FMR1 premutation. Scientific Reports, 2020, 10, 16059.	1.6	3

#	Article	IF	Citations
289	Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome. Brain Sciences, 2020, 10, 361.	1.1	3
290	Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder. Frontiers in Genetics, 2020, 11, 308.	1.1	3
291	Inequities in diagnosis of Fragile X syndrome in Colombia. Journal of Applied Research in Intellectual Disabilities, 2021, 34, 830-839.	1.3	3
292	Hispanoâ€American Brain Bank on Neurodevelopmental Disorders: An initiative to promote brain banking, research, education, and outreach in the field of neurodevelopmental disorders. Brain Pathology, 2022, 32, e13019.	2.1	3
293	Molecular-clinical correlations in males with an expanded FMR1 mutation. , 1996, 64, 388.		3
294	Fentanyl overdose in a female with the premutation and FXTAS. , 2018, 1, .		3
295	Turning the tide on targeted treatments for neurodevelopmental disorders. Neurology, 2019, 92, 741-742.	1.5	2
296	Clinical and Molecular Assessment in a Female with Fragile X Syndrome and Tuberous Sclerosis. Journal of Genetic Disorders & Genetic Reports, 2016, 5, .	0.1	1
297	Recent research in fragile X-associated tremor/ataxia syndrome. Current Opinion in Neurobiology, 2022, 72, 155-159.	2.0	1
298	Prosaccade and Antisaccade Behavior in Fragile Xâ€associated Tremor/Ataxia Syndrome Progression. Movement Disorders Clinical Practice, 2022, 9, 473-478.	0.8	1
299	Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries?. Yale Journal of Biology and Medicine, 2021, 94, 559-571.	0.2	1
300	Response to letter: â€œNo evidence of paternal transmission of fragile X syndromeâ€•by Doris and Peter Steinbach. American Journal of Medical Genetics, Part A, 2005, 136A, 109-110.	0.7	0
301	Translational research guided by animal studies in Fragile X Disorders. Intractable and Rare Diseases Research, 2014, 3, 100-100.	0.3	0
302	The Fragile X Mouse is Cured, Now for the Patients. Human Mutation, 2014, 35, v-v.	1.1	0
303	Psychopathology Increases With Age in Fragile X Carrier Mothers. Biological Psychiatry, 2016, 79, 790-791.	0.7	0
304	Cognitive Deficits and Associated ERP N400 Abnormalities in FXTAS With Parkinsonism. Frontiers in Genetics, 2018, 9, 327.	1.1	0